Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study

被引:14
作者
Lam, Laurent [1 ,2 ]
Fontaine, Helene [3 ]
Bourliere, Marc [4 ]
Lusivika-Nzinga, Clovis [2 ]
Dorival, Celine [2 ]
Thabut, Dominique [5 ]
Zoulim, Fabien [6 ]
Habersetzer, Francois [7 ,8 ]
Asselah, Tarik [9 ]
Duclos-Vallee, Jean-Charles [10 ]
Bronowicki, Jean-Pierre [11 ,12 ]
Mathurin, Philippe [13 ,14 ]
Decaens, Thomas [15 ]
Ganne, Nathalie [16 ,17 ,18 ]
Guyader, Dominique [19 ]
Leroy, Vincent [20 ]
Rosa, Isabelle [21 ]
De Ledinghen, Victor [22 ,23 ]
Cales, Paul [24 ,25 ]
Causse, Xavier [26 ]
Larrey, Dominique [27 ]
Chazouilleres, Olivier [28 ]
Gelu-Simeon, Moana [29 ,30 ]
Loustaud-Ratti, Veronique [31 ]
Metivier, Sophie [32 ]
Alric, Laurent [33 ]
Riachi, Ghassan [34 ]
Gournay, Jerome [35 ]
Minello, Anne [36 ]
Tran, Albert [37 ]
Geist, Claire [38 ]
Abergel, Armand [39 ,40 ]
Raffi, Francois [41 ]
D'Alteroche, Louis [42 ]
Portal, Isabelle [43 ]
Lapidus, Nathanael [1 ,2 ]
Pol, Stanislas [3 ,44 ,45 ,46 ]
Carrat, Fabrice [1 ,2 ]
机构
[1] Sorbonne Univ, Dept Publ Hlth, Hop St Antoine, AP HP, Paris, France
[2] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Paris, France
[3] Hop Cochin, AP HP, Dept Hepatol, Paris, France
[4] Hop St Joseph, Dept Hepatol & Gastroenterol, Marseille, France
[5] Sorbonne Univ, Grp Hosp Pitie Salpetriere, AP HP, Dept Hepatol & Gastroenterol,INSERM UMR S938, Paris, France
[6] Univ Lyon, Hosp Civils Lyon, Dept Hepatol, INSERM U1052, Lyon, France
[7] Univ Strasbourg, CIC, Inserm 1110, Strasbourg, France
[8] Univ Strasbourg, Pole Hepatodigestif Hop Univ Strasbourg, Strasbourg, France
[9] Univ Paris Diderot, Ctr Rech Sur Inflammat CRI, INSERM UMR 1149, Hepatol,Hosp Beaujon, Clichy, France
[10] Univ Paris Saclay, Hop Paul Brousse, AP HP, Ctr Hepatobiliaire,UMR S 1193,DHU HEPATINOV, Villejuif, France
[11] Univ Lorraine, Inserm U1254, Univ Hosp Nancy Brabois, Vandoeuvre Les Nancy, France
[12] Univ Lorraine, Dept Hepatogastroenterol, Univ Hosp Nancy Brabois, Vandoeuvre Les Nancy, France
[13] Univ Lille 2, Serv Malad Appareil Digestif, Lille, France
[14] Inserm U795, Paris, France
[15] Univ Grenoble Alpes, Dept Hepatol & Gastroenterol, INSERM U1209, Ctr Hosp Univ, Grenoble, France
[16] Hop Univ Paris Seine St Denis, AP HP, Dept Hepatol, Site Jean Verdier, Bondy, France
[17] Univ Paris 13, Sorbonne Paris Cite, Paris, France
[18] INSERM UMR 1162, Paris, France
[19] CHU Rennes, Serv Hepatol, Univ Rennes 1,UMR A 1341,UMR S 1241, Inra,Inserm,Inst NUMECAN Nutr Metabolismes & Canc, Rennes, France
[20] Univ Paris Est, Hop Henri Mondor, AP HP, Dept Hepatol & Gastroenterol,INSERM U955, Creteil, France
[21] Ctr Hosp Intercommunal, Dept Hepatol & Gastroenterol, Creteil, France
[22] Bordeaux Univ, Univ Hosp Bordeaux, Hepatol Unit, Pessac, France
[23] Bordeaux Univ, INSERM U1053, Pessac, France
[24] Univ Hosp, Hepatol Dept, Angers, France
[25] Angers Univ, HIFIH Lab, Angers, France
[26] CHR Orleans, Dept Hepatol & Gastroenterol, Orleans, France
[27] Hop St Eloi, Liver Unit, IRB INSERM 1183, Montpellier, France
[28] Sorbonne Univ, Hop St Antoine, AP HP, Dept Hepatol, Paris, France
[29] Univ Antilles, CHU Guadeloupe, Serv Hepatogastroenterol, Fac Med, F-97110 Pointe A Pitre, Guadeloupe, France
[30] INSERM, UMR S1085, IRSET, F-35043 Rennes, France
[31] Univ Limoges, U1248 INSERM, CHU Limoges, Dept Hepatol & Gastroenterol, F-87000 Limoges, France
[32] CHU Rangueil, Hepatol Unit, F-31059 Toulouse, France
[33] IRD Toulouse 3 Univ, Dept Internal Med & Digest Dis, UMR Pharma Dev 152, CHU Purpan, Toulouse, France
[34] CHU Charles Nicolle, Dept Hepatol & Gastroenterol, Rouen, France
[35] Univ Hosp Nantes, Gastroenterol & Hepatol Dept, Inst Malad Appareil Digestif, Nantes, France
[36] Univ Hosp Dijon, Dept Hepatol & Gastroenterol, INSERM UMR 1231, Dijon, France
[37] Ctr Hosp Univ Nice, Digest Ctr, INSERM U1065 8, Nice, France
[38] Ctr Hosp Reg, Dept Hepatol & Gastroenterol, Metz, France
[39] Estaing Univ Hosp, Dept Digest & Hepatobiliary Dis, Clermont Ferrand, France
[40] Sigma Univ Clermont Auvergne, UMR CNRS 6602, Clermont Ferrand, France
[41] Nantes Univ Hosp, Hotel Dieu Hosp, Dept Infect Dis, INSERM CIC 1413, Nantes, France
[42] Unit Hepatol, CHU Trousseau, Hepatogastroenterol, F-37044 Tours, France
[43] Aix Marseille Univ, Serv Hepatogastroenterol, AP HM, Hop Timone, Marseille, France
[44] Univ Paris, Paris, France
[45] Inst Pasteur, Inserm U1223, Paris, France
[46] Inst Pasteur, ICD, Paris, France
关键词
Hepatocellular carcinoma; Hepatitis B virus; Hepatocarcinogenesis; Liver cancer; Epidemiology; NATURAL-HISTORY; VIRUS-INFECTION; RISK-FACTORS; EPIDEMIOLOGY; INCREASES; CIRRHOSIS; EMPHASIS; CANCER;
D O I
10.1016/j.clinre.2021.101713
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The factors predicting hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B need to be precisely known to improve its detection. We identified pathways and individual predictive factors associated with HCC in the ANRS CO22 HEPATHER cohort. Methods: The study analyzed HBV-infected patients recruited at 32 French expert hepatology centers from August 6, 2012, to December 31, 2015. We excluded patients with chronic HCV, HDV and a history of HCC, decompensated cirrhosis or liver transplantation. Structural equation models were developed to characterize the causal pathways leading to HCC occurrence. The association between clinical characteristics (age, gender, body-mass index, liver fibrosis, alcohol consumption, smoking status, diabetes, hypertension, dyslipidemia, alpha-fetoprotein, HBV DNA levels, antiviral therapy) and incident HCC was quantified. Results. - Among the 4489 patients included, 33 patients reported incident HCC. The median follow-up was 45.5 months. Age (beta = 0.18 by decade, 95% CI 0.14-0.23), male gender (beta = 0.23, 95% CI 0.18-0.29), metabolic syndrome (beta = 0.28, 95% CI 0.22-0.33), alcohol consumption (beta = 0.09, 95% CI 0.05-0.14) and HBV DNA (beta = 0.25, 95% CI 0.170.34) had a significant and direct effect on the occurrence of advanced liver fibrosis. Liver fibrosis (beta = 0.71, 95% CI 0.55-0.87) predicted, in turn, the occurrence of HCC. Conclusions. - Liver fibrosis mediates the effects of age, gender, alcohol, metabolic syndrome and HBV DNA on the occurrence of HCC. Elderly men with chronic hepatitis B, risky alcohol use, advanced liver fibrosis, metabolic syndrome and high HBV DNA levels should be monitored closely to detect the development of HCC. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:14
相关论文
共 49 条
  • [1] Abdel-Rahman Omar, 2017, J Evid Based Med, V10, P245, DOI 10.1111/jebm.12270
  • [2] Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection
    Adams, LA
    Bulsara, M
    Rossi, E
    Deboer, B
    Speers, D
    George, J
    Kench, J
    Farrell, G
    McCaughan, GW
    Jeffrey, GP
    [J]. CLINICAL CHEMISTRY, 2005, 51 (10) : 1867 - 1873
  • [3] BEASLEY RP, 1981, LANCET, V2, P1129
  • [4] An algorithm for the grading of activity in chronic hepatitis C
    Bedossa, P
    Poynard, T
    [J]. HEPATOLOGY, 1996, 24 (02) : 289 - 293
  • [5] Natural history of hepatitis-related hepatocellular carcinoma
    But, David Yiu-Kuen
    Lai, Ching-Lung
    Yuen, Man-Fung
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (11) : 1652 - 1656
  • [6] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chen, CJ
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Lu, SN
    Huang, GT
    Iloeje, UH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01): : 65 - 73
  • [7] Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls
    Chen, SY
    Wang, LY
    Lunn, RM
    Tsai, WY
    Lee, PH
    Lee, CS
    Ahsan, H
    Zhang, YJ
    Chen, CJ
    Santella, RM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (01) : 14 - 21
  • [8] RETRACTED: Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study (Retracted Article)
    Choi, Jonggi
    Kim, Hyo Jeong
    Lee, Jayoun
    Cho, Songhee
    Ko, Min Jung
    Lim, Young-Suk
    [J]. JAMA ONCOLOGY, 2019, 5 (01) : 30 - 36
  • [9] Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance
    Chon, Y. E.
    Jung, K. S.
    Kim, M. -J.
    Choi, J. -Y.
    An, C.
    Park, J. Y.
    Ahn, S. H.
    Kim, B. K.
    Kim, S. U.
    Park, H.
    Hwang, S. K.
    Rim, K. S.
    Han, K. -H.
    Kim, D. Y.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (08) : 1201 - 1212
  • [10] Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
    Chu, CM
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2000, 15 : E25 - E30